List of Contract Manufacturing Companies in United Kingdom - 22
Search through the full list with powerful filtering options
Want this in Excel? Get Quote NowCompany | About |
---|---|
Abingdon Health plc York Biotech Campus, Sand Hutton, York, YO41 1LZ, GB | We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways. |
Antibody Production Services Ltd. northside house, bedford, herts, united kingdom | |
Ascend Advanced Therapies London, United Kingdom | Ascend is a development partner that supports life-science innovators in bringing gene therapy products to patients. Our team has deep expertise in gene therapy development and commercialization to offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together! |
BBI Solutions Bleanavon, United Kingdom | BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence |
Cellesce Ltd Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, Cardiff, Cardiff CF14 4UJ, GB | Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine. |
Cobra Biologics 251 ballardvale street, keele, staffordshire, united kingdom | Cobra Biologics, a Charles River company, is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The team at Cobra's GMP approved facilities has expertise tailored to serving customers around the world; offering a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. |
eXmoor Pharma Britannia Road, Patchway, Bristol, BS34 5TA, GB | eXmoor is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years consultancy experience supporting over 150 organisations accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release. We are open, transparent and will work with you at every step to de-risk and streamline your project and maximise the chances of product success. |
Fujifilm Diosynth Billingham, United Kingdom | For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB. |
Leaf Expression Systems Norwich, England, United Kingdom | Leaf Expression Systems is a translational R&D and contract manufacturing business focused on the plant expression of proteins, vaccines, and complex natural products. They use the power of plant-based expression and plant biotechnology to enable their partners to innovate and impact, helping to drive their productivity and create. |
Lentitek Edinburgh, Scotland, United Kingdom | Based in Edinburgh, Scotland. Lentitek has pioneered the development of alternative approaches to lentiviral vector production based on novel promoter technology conceived by Dr Adam Inche. The Lentitek platform was developed to address key issues limiting progression of ATMP assets and is now enabling the use of retrovirus based vectors in new and previously unviable applications. Unique properties of the Lentitek platform can be leveraged to enable in-vivo CAR-T and armoured CAR applications in addition to addressing quality and yield inconsistencies within ex-vivo CAR-T manufacture. The Lentitek platform is accessed through a serviced CRO license model where Lentiteks’ renowned team of vector design specialists work with asset developers to integrate the Ltek solution and validate performance including transfer to chosen manufacturing partner. |
NunaBio Limited 32 gallowgate, newcastle upon tyne, tyne and wear, united kingdom | NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio's core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies. |
Oxford Biomedica Oxford, England | OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. |
Oxford Genetics Oxford, United Kingdom | Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines. |
Quotient Sciences Edinburgh, United Kingdom | Provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. |
RoslinCT Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX, GB | RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com. |
Symbiosis Pharmaceutical Services Stirling, United Kingdom | Symbiosis Pharmaceutical Services is a contract manufacturing organisation (CMO) that specialises in the GMP manufacture and sterile fill/finish of vials for clinical trials and low-volume commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core. Manufacturing takes place in a purpose-built MHRA-licensed and FDA approved facility, enabling the CMO to handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs. Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product manufacturing, while maintaining regulatory compliance to the highest standards. Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials, which are either liquid or lyophilised formulations. Capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules. Symbiosis saves our clients invaluable development time. With short lead times to manufacture and faster release of sterile drug product, we get you into phase I/II quickly. Our focus is service excellence through flexibility, responsiveness and timeliness. If you need a drug filled aseptically, come and speak with Symbiosis...we will exceed your expectations. |
SynGenSys 5th Floor, 3 Saint Pauls Place, 129 Norfolk Street, Sheffield S1 2JE, England | SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose. |
Torbay Pharma Paignton, Devon | Torbay Pharma is a licence holder and global specialist in the manufacture and supply of terminally sterilized injectables for the hospital market. We work with generic pharmaceutical companies seeking to ensure their sterile injectable products get to market reliably and without delay. As a CMO and CDMO, we offer fill/finish services for terminally sterilised injectables into plastic and glass vials and ampoules. Our specialist portfolio includes licensed and unlicensed terminally sterilised injectables, electrolyte solutions for total parenteral nutrition (TPN) compounding and a range of non-sterile oral solutions. Established in the 1970s as part of the Torbay and Devon NHS Foundation Trust, we have grown into a 250-strong team operating from our purpose built manufacturing facility in Paignton, UK. November 2023 saw us receive investment from NorthEdge, we’re now Torbay Pharmaceuticals Ltd. Torbay Pharma offer niche product experience and capabilities, an agile approach and a team of experts who genuinely care. Our determination and flexibility at every step, ensure quality products are efficiently supplied to market, with clear communication and consultancy throughout the process. If you think we can help you with your next project, visit our website: www.torbaypharma.com |
Touchlight DNA Services London, England | |
Trisk Bio london, england, united kingdom | Manufacturing. |
Vectura Wiltshire, United Kingdom | Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com |
ViroCell Biologics London, England |